R2 Technologies – Huadong Medicine Company Limited
R2 Technologies is the world leader in CryoAesthetics™ medical devices. Our Glacial® platform for precision contact cooling of the skin has been shown to reduce inflammation and also brighten dark spots.
Huadong makes an equity investment in R2 Dermatology
R2 Dermatology (“R2”) announced today that it has entered into an exclusive distribution agreement with China’s Huadong Medicine Company Limited (“Huadong”) for the Asia-Pacific Region. In exchange, Huadong will make an equity investment in R2 Dermatology to fund R2’s next phase of product and market development.
R2 Dermatology was founded in late 2014 by Pansend Life Sciences (a subsidiary of HC2 Holdings, Inc.) and Blossom Innovations. Since inception, R2 has generated substantial safety and efficacy studies in several multi-center clinical studies both in North America and Asia. In addition, R2 has received two US FDA 510(k) clearances for its clinical stage devices. Powered by licensed IP from Blossom Innovations and Massachusetts General Hospital, R2’s platform will provide a unique patient experience: safe, comfortable treatments with no downtime and predictable, efficacious outcomes.
